1. Freudenthal, H. D.Transactions of the Drugs from the Sea Symposium, University of Rhode Island, 27–29 August 1967 1–297 (Marine Technology Society, Washington, DC, 1968).

   Google Scholar 

2. Newman D. J. & Cragg G. M. Marine natural products and related compounds in clinical and advanced preclinical trials.J. Nat. Prod.67, 1216–1238 (2004).

   Article CAS PubMed  Google Scholar 

3. Newman D. J. & Cragg G. M. Natural products as sources of new drugs over the last 25 years.J. Nat. Prod.70, 461–477 (2007).

   Article CAS PubMed  Google Scholar 

4. Newman, D. J. & Cragg, G. M. inMarine Anticancer Compounds in the Era of Targeted therapies 1st edn (ed. Chapner, B.) (Permanyer Publications, Barcelona, 2008).

   Google Scholar 

5. Bergmann, W. & Feeney R. J. Contributions to the study of marine products. XXXII. The nucleosides of sponges. I.J. Org. Chem.16, 981–987 (1951).

   Article CAS  Google Scholar 

6. Bergmann, W. & Burke, D. C. Contributions to the study of marine products. XL. The nucleosides of sponges. IV. Spongosine.J. Org. Chem.22, 226–228 (1956).

   Article  Google Scholar 

7. Bergmann, W. & Stempien, M. F. Contributions to the study of marine products. XLIII. The nucleosides of sponges. V. The synthesis of spongosine.J. Org. Chem.22, 1575–1557 (1957).

   Article CAS  Google Scholar 

8. Koehn, F. E. & Carter, G. T. The evolving role of natural products in drug discovery.Nature Rev. Drug Discovery4, 206–220 (2004).This important, prescient review from scientists in a large pharmaceutical drug discovery programme presents the technical and logistical challenges for natural products discovery.

   Article CAS  Google Scholar 

9. Jarvis, L. M. Liquid gold mine.Chem. Engin. News85, 22–28 (2007).

   Google Scholar 

10. Mendola, D. inDrugs from the Sea (ed. Fusetani, N.) 120–133 (Karger, Basel, 2000).

    Book  Google Scholar 

11. Olivera, B. M. et al. Peptide neurotoxins from fish-hunting cone snails.Science230, 1338–1343 (1985).

    Article CAS PubMed  Google Scholar 

12. Terlau, H. & Olivera, B. M.Conus venoms: a rich source of novel ion channel-targeted peptides.Physiol. Rev.84, 41–68 (2004).

    Article CAS PubMed  Google Scholar 

13. Olivera, B. M., Miljanich, G. P., Ramachandran, J. & Adams, M. E. Calcium-channel diversity and neurotransmitter release — the ω-conotoxins and ω-agatoxins.Ann. Rev. Biochem.63, 823–867 (1994).

    Article CAS PubMed  Google Scholar 

14. Chung, D., Gaur, S., Bell, J. R., Ramachandran, J. & Nadasdi, L. Determination of disulfide bridge pattern in ω-conopeptides.Int. J. Pept. Protein Res.46, 320–325 (1995).

    Article CAS PubMed  Google Scholar 

15. Price-Carter, M., Hull, M. S. & Goldenberg, D. P. Roles of individual disulfide bonds in the stability and folding of an ω-conotoxin.Biochemistry37, 9851–9861 (1998).

    Article CAS PubMed  Google Scholar 

16. Olivera, B. M. et al. Neuronal calcium-channel antagonists — discrimination between calcium-channel subtypes using ω-conotoxin fromConus magus venom.Biochemistry26, 2086–2090 (1987).

    Article CAS PubMed  Google Scholar 

17. Yeager, R. E., Yoshikami, D., Rivier, J., Cruz, L. J. & Miljanich, G. P. Transmitter release from presynaptic terminals of electric organ: inhibition by the calcium channel antagonist ωConus toxin.J. Neurosci.7, 2390–2396 (1987).

    CAS PubMed PubMed Central  Google Scholar 

18. Atkinson, R. A., Kieffer, B., Dejaegere, A., Sirockin, F. & Lefevre, J. F. Structural and dynamic characterization of ω -conotoxin MVIIA: the binding loop exhibits slow conformational exchange.Biochemistry39, 3908–3919 (2000).

    Article CAS PubMed  Google Scholar 

19. Kim, J. I., Takahashi, M., Ohtake, A., Wakamiya, A. & Sato, K. Tyr13 Is essential for the activity of ω -conotoxin MVIIA and GVIA, specific N-type calcium channel blockers.Biochem. Biophys. Res. Commun.206, 449–454 (1995).

    Article CAS PubMed  Google Scholar 

20. Gohil, K., Bell, J. R., Ramachandran, J. & Miljanich, G. P. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (ω -conopeptide MVIIC).Brain Res.653, 258–266 (1994).

    Article CAS PubMed  Google Scholar 

21. Bowersox, S. S. et al. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain.J. Pharmacol. Exp. Ther.279, 1243–1249 (1996).

    CAS PubMed  Google Scholar 

22. Kristipati, R. et al. Characterization of the binding of ω -conopeptides to different classes of non-L-type neuronal calcium channels.Mol. Cell. Neurosci.5, 219–228 (1994).

    Article CAS PubMed  Google Scholar 

23. Jones, R. M. et al. Composition and therapeutic utility of conotoxins from genusConus. Patent status 1996–2000Exp. Opin. Ther. Patents11, 603–623 (2001).

    Article CAS  Google Scholar 

24. Bowersox, S. S. & Luther, R. Pharmacotherapeutic potential of ω-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom ofConus magus.Toxicon36, 1651–1658 (1998).

    Article CAS PubMed  Google Scholar 

25. Wang, Y. X., Pettus, M., Gao, D., Phillips, C. & Scott Bowersox, S. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain.Pain84, 151–158 (2000).

    Article CAS PubMed  Google Scholar 

26. Miljanich, G. P. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.Curr. Med. Chem.11, 3029–3040 (2004).

    Article CAS PubMed  Google Scholar 

27. Garber, K. Peptide leads new class of chronic pain drugs.Nature Biotech.23, 399 (2005).

    Article CAS  Google Scholar 

28. Heading, C. E.Conus toxins: targets and properties.IDrugs7, 1011–1016 (2004).

    CAS PubMed  Google Scholar 

29. Sigel, M. M. et al. inFood–Drugs from the Sea: Proceedings (ed. Youngken, H. W. Jr) 281–294 (Marine Technology Society, Washington, DC, 1969).

    Google Scholar 

30. Rinehart, K. L. et al. Ecteinascidin-729, Ecteinascidin-743, Ecteinascidin-745, Ecteinascidin-759a, Ecteinascidin-759b, and Ecteinascidin-770 — potent antitumor agents from the Caribbean tunicateEcteinascidia turbinata.J. Org. Chem.55, 4512–4515 (1990).

    Article CAS  Google Scholar 

31. Wright, A. E. et al. Antitumor tetrahyrodisoquinoline alkaloids from the colonial ascidianEcteinascidia turbinata.J. Org. Chem.55, 4508–4512 (1990).

    Article CAS  Google Scholar 

32. Sakai, R., Rinehart, K. L., Guan, Y. & Wang, A. H. Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activitiesin vivo.Proc. Nat. Acad. Sci. USA89, 11456–11460 (1992).

    Article CAS PubMed PubMed Central  Google Scholar 

33. Corey, E. J., Gin, D. Y. & Kania, R. S. Enantioselective total synthesis of ecteinascidin 743.J. Am. Chem. Soc.118, 9202–9203 (1996).

    Article CAS  Google Scholar 

34. Martinez, E. J. & Corey, E. J. A new, more efficient, and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents.Org. Lett.2, 993–996 (2000).

    Article CAS PubMed  Google Scholar 

35. Cuevas, C. et al. Synthesis of ecteinascidin ET-743 and Phthalascidin Pt-650 from cyanosafracin B.Org. Lett.2, 2545–2548 (2000).

    Article CAS PubMed  Google Scholar 

36. Aune, G. J., Furuta, T. & Pommier, Y. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.Anticancer Drugs13, 545–555 (2002).

    Article CAS PubMed  Google Scholar 

37. Pommier, Y. et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicateEcteinascidia turbinata.Biochemistry35, 13303–13309 (1996).

    Article CAS PubMed  Google Scholar 

38. Zewail-Foote, M. & Hurley, L. H. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.J. Med. Chem.42, 2493–2497 (1999).

    Article CAS PubMed  Google Scholar 

39. Zewail-Foote, M. et al. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.Chem. Biol.8, 1033–1049 (2001).

    Article CAS PubMed  Google Scholar 

40. Takebayashi, Y. et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.Nature Med.7, 961–966 (2001).An excellent technical paper describing the excision repair inhibition mechanism that is unique to ET-743.

    Article CAS PubMed  Google Scholar 

41. Di Leo, P. et al. Final results of a phase II trial of 3-HR infusion trabectedin in patients with recurrent sarcomas.Ann. Oncol.17, 167–167 (2006).

    Article  Google Scholar 

42. Paz-Ares, L. et al. Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.Clin. Colorectal Cancer6, 522–528 (2007).

    Article CAS PubMed  Google Scholar 

43. Zelek, L. et al. A phase II study of Yondelis^® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancerBr. J. Cancer94, 1610–1614 (2006).

    Article CAS PubMed PubMed Central  Google Scholar 

44. Sessa, C. et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.J. Clin. Oncol.23, 1867–1874 (2005).

    Article CAS PubMed  Google Scholar 

45. Yovine, A. et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.J. Clin. Oncol.22, 890–899 (2004).

    Article CAS PubMed  Google Scholar 

46. Jimeno, J. et al. Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma.Curr. Op. Orthopaed.14, 419–428 (2003).

    Article  Google Scholar 

47. Jimeno, J. et al. Progress in the clinical development of new marine-derived anticancer compounds.Anticancer Drugs15, 321–329 (2004).

    Article CAS PubMed  Google Scholar 

48. Ryan, D. P. et al. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.Oncologist7, 531–538 (2002).

    Article CAS PubMed  Google Scholar 

49. Blay, J. Y. et al. A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.Eur. J. Cancer40, 1327–1331 (2004).

    Article CAS PubMed  Google Scholar 

50. Meco, D. et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.Cancer Chemother. Pharmacol.52, 131–138 (2003).

    Article CAS PubMed  Google Scholar 

51. Takahashi, N., Li, W. W., Banerjee, D., Scotto, K. W. & Bertino, J. R. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.Clin. Canc. Res.7, 3251–3257 (2001).

    CAS  Google Scholar 

52. Riccardi, A. et al. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.Anticancer Drugs16, 811–815 (2005).

    Article CAS PubMed  Google Scholar 

53. Brandon, E. F. A. et al.In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.Anticancer Drugs16, 935–943 (2005).

    Article CAS PubMed  Google Scholar 

54. Donald, S. et al. Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytesin vitro.Cancer Chemother. Pharmacol.53, 305–312 (2004).

    Article CAS PubMed  Google Scholar 

55. Donald, S. et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.Cancer Res.63, 5902–5908 (2003).

    CAS PubMed  Google Scholar 

56. Beumer, J. H., Schellens, J. H. & Beijnen, J. H. Hepatotoxicity and metabolism of trabectedin: a literature review.Pharmacol. Res.51, 391–398 (2005).

    Article CAS PubMed  Google Scholar 

57. Chun, H. G. et al. Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent.Invest. New Drugs4, 279–284 (1986).

    Article CAS PubMed  Google Scholar 

58. Vera, M. D. & Joullie, M. M. Natural products as probes of cell biology: 20 years of didemnin research.Med. Res. Rev.22, 102–145 (2002).

    Article CAS PubMed  Google Scholar 

59. Rinehart, K. Antitumor Compounds from Tunicates.Med. Res. Rev.1, 1–27 (2003).

    Google Scholar 

60. Rinehart, K. L. Jr., Gloer, J. B., Cook, J. C., Mizsak, S. A. & Scahill, T. A. Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Carribean tunicate.J. Am. Chem. Soc.103, 1857–1859 (1981).

    Article CAS  Google Scholar 

61. Rinehart, K. L. Jr et al. Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate.Science212, 933–935 (1981).

    Article CAS PubMed  Google Scholar 

62. Rinehart, K. L. Jr et al. Total synthesis of didemnins A, B, and C.J. Am. Chem. Soc.109, 6856–6848 (1987).

    Google Scholar 

63. McKee, T. C., Ireland, C. M., Lindquist, N. & Fenical, W. The complete spectral assignment of didemnin B and nordidemnin B.Tetrahedron Lett.30, 3053–3056 (1989).

    Article CAS  Google Scholar 

64. Gloer, J. B.Structures of the Didemnins. Thesis, Univ. Illinois (1983).

    Google Scholar 

65. Hossain, M. B. et al. Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide.Proc. Natl Acad. Sci. USA85, 4118–4122 (1988).

    Article CAS PubMed PubMed Central  Google Scholar 

66. Meng, L., Sin, N. & Crews, C. M. The antiproliferative agent didemnin B uncompetitively inhibits palmitoyl protein thioesterase.Biochemistry37, 10488–10492 (1998).

    Article CAS PubMed  Google Scholar 

67. Crews, C. M., Lane, W. S. & Schreiber, S. L. Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis.Proc. Natl Acad. Sci. USA93, 4316–4319 (1996).

    Article CAS PubMed PubMed Central  Google Scholar 

68. Li, L. H. et al. Mechanism of action of didemnin B, a depsipeptide from the sea.Cancer Lett.23, 279–288 (1984).

    Article CAS PubMed  Google Scholar 

69. SirDeshpande, B. V. & Toogood, P. L. Mechanism of protein synthesis inhibition by didemnin Bin vitro.Biochemistry34, 9177–9184 (1995).

    Article CAS PubMed  Google Scholar 

70. Ahuja, D. et al. Inhibition of protein synthesis by didemnin B: how EF-1a mediates inhibition of translocation.Biochemistry39, 4339–4346 (2000).

    Article CAS PubMed  Google Scholar 

71. Marco, E., Martin-Santamaria, S., Cuevas, C. & Gago, F. Structural basis for the binding of didemnins to human elongation factor eEF1A and rationale for the potent antitumor activity of these marine natural products.J. Med. Chem.47, 4439–4452 (2004).

    Article CAS PubMed  Google Scholar 

72. Crews, C. M., Collins, J. L., Lane, W. S., Snapper, M. L. & Schreiber, S. L. GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 α.J. Biol. Chem.269, 15411–15414 (1994).Illustrates the 'chemical biological' approach to the identification of protein targets of natural product drugs, and the importance of discriminating high- and low-affinity binding partners (see also reference67)

    Article CAS PubMed  Google Scholar 

73. Beidler, D. R., Ahuja, D., Wicha, M. S. & Toogood, P. L. Inhibition of protein synthesis by didemnin B is not sufficient to induce apoptosis in human mammary carcinoma (MCF7) cells.Biochem. Pharmacol.58, 1067–1074 (1999).

    Article CAS PubMed  Google Scholar 

74. Erba, E. et al. Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine.Br. J. Cancer86, 1510–1517 (2002).

    Article CAS PubMed PubMed Central  Google Scholar 

75. Johnson, K. L., Vaillant, F. & Lawen, A. Protein tyrosine kinase inhibitors prevent didemnin B-induced apoptosis in HL-60 cells.FEBS Lett.383, 1–5 (1996).

    Article CAS PubMed  Google Scholar 

76. Johnson, K. L. & Lawen, A. Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25.Immunol. Cell Biol.77, 242–248 (1999).

    Article CAS PubMed  Google Scholar 

77. Weed, S. D. & Stringfellow, D. A. Didemnins A and B. Effectiveness against cutaneous herpes simplex virus in mice.Antiviral Res.3, 269–274 (1983).

    Article CAS PubMed  Google Scholar 

78. Urdiales, J. L., Morata, P., Nunez De Castro, I. & Sanchez-Jimenez, F. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates.Cancer Lett.102, 31–37 (1996).

    Article CAS PubMed  Google Scholar 

79. Dorr, F. A., Kuhn, J. G., Phillips, J. & von Hoff, D. D. Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide.Eur. J. Cancer Clin. Oncol.24, 1699–1706 (1988).

    Article CAS PubMed  Google Scholar 

80. Scheithauer, W., Moyer, M. P., Clark, G. M. & Von Hoff, D. D. Application of a new preclinical drug screening system for cancer of the large bowel.Cancer Chemother. Pharmacol.21, 31–34 (1988).

    Article CAS PubMed  Google Scholar 

81. Grubb, D. R., Wolvetang, E. J. & Lawen, A. Didemnin B induces cell death by apoptosis: the fastest induction of apoptosis ever described.Biochem. Biophys. Res. Commun.215, 1130–1136 (1995).

    Article CAS PubMed  Google Scholar 

82. Geldof, A. A., Mastbergen, S. C., Henrar, R. E. & Faircloth, G. T. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated usingin vitro assays.Cancer Chemother. Pharmacol.44, 312–318 (1999).

    Article CAS PubMed  Google Scholar 

83. Stewart, J. A., Low, J. B., Roberts, J. D. & Blow, A. A phase I clinical trial of didemnin B.Cancer68, 2550–2554 (1991).

    Article CAS PubMed  Google Scholar 

84. Maroun, J. A., Stewart, D., Verma, S. & Eisenhauer, E. Phase I clinical study of didemnin B.Invest. New Drugs16, 51–56 (1998).

    Article CAS PubMed  Google Scholar 

85. Shin, D. M. et al. Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting.Cancer Chemother. Pharmacol.29, 145–149 (1991).

    Article CAS PubMed  Google Scholar 

86. Benvenuto, J. A. et al. Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer.Invest. New Drugs10, 113–117 (1992).

    Article CAS PubMed  Google Scholar 

87. Shin, D. M. et al. Phase II clinical trial of didemnin B in previously treated small cell lung cancer.Invest. New Drugs12, 243–249 (1994).

    Article CAS PubMed  Google Scholar 

88. Goss, G. et al. Didemnin B in favorable histology non-Hodgkin's lymphoma: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.Invest. New Drugs13, 257–260 (1995).

    Article CAS PubMed  Google Scholar 

89. Kucuk, O. et al. Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study.Am. J. Clin. Oncol.23, 273–277 (2000).

    Article CAS PubMed  Google Scholar 

90. Hochster, H., Oratz, R., Ettinger, D. S. & Borden, E. A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687).Invest. New Drugs16, 259–263 (1999).

    Article CAS  Google Scholar 

91. Mittelman, A. et al. Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).Invest. New Drugs17, 179–182 (1999).

    Article CAS PubMed  Google Scholar 

92. Taylor, S. A. et al. Phase II study of didemnin B in central nervous system tumors: a Southwest Oncology Group study.Invest. New Drugs16, 331–332 (1999).

    Article CAS  Google Scholar 

93. Nuijen, B. et al. Pharmaceutical development of anticancer agents from marine sources.Anticancer Drugs11, 793–811 (2000).

    Article CAS PubMed  Google Scholar 

94. Rinehart, K. L. & Lithgow-Bertelloni, A. M. Dehydrodidemnin B. WO9104985 (A1) (1991).

95. Garcia-Fernandez, L. F. et al. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C.Oncogene21, 7533–7544 (2002).

    Article CAS PubMed  Google Scholar 

96. Gajate, C., An, F. & Mollinedo, F. Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95- and mitochondrial-mediated mechanism.Clin. Cancer Res.9, 1535–1545 (2003).

    CAS PubMed  Google Scholar 

97. Grubb, D. R., Ly, J. D., Vaillant, F., Johnson, K. L. & Lawen, A. Mitochondrial cytochromec release is caspase-dependent and does not involve mitochondrial permeability transition in didemnin B-induced apoptosis.Oncogene20, 4085–4094 (2001).

    Article CAS PubMed  Google Scholar 

98. Cuadrado, A. et al. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK.J. Biol. Chem.278, 241–250 (2003).

    Article CAS PubMed  Google Scholar 

99. Cuadrado, A., Gonzalez, L., Suarez, Y., Martinez, T. & Munoz, A. JNK activation is critical for Aplidin-induced apoptosis.Oncogene23, 4673–4680 (2004).

    Article CAS PubMed  Google Scholar 

100. Broggini, M. et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF–VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.Leukemia17, 52–59 (2003).

     Article CAS PubMed  Google Scholar 

101. Biscardi, M. et al. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia.Ann. Oncol.16, 1667–1674 (2005).

     Article CAS PubMed  Google Scholar 

102. Losada, A., Lopez-Oliva, J. M., Sanchez-Puelles, J. M. & Garcia-Fernandez, L. F. Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin.Br. J. Cancer91, 1405–1413 (2004).

     Article CAS PubMed PubMed Central  Google Scholar 

103. Erba, E. et al. Effect of aplidine in acute lymphoblastic leukaemia cells.Br. J. Cancer89, 763–773 (2003).

     Article CAS PubMed PubMed Central  Google Scholar 

104. Albella, B. et al.In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.Eur. J. Cancer38, 1395–1404 (2002).

     Article CAS PubMed  Google Scholar 

105. Baker, M. A., Grubb, D. R. & Lawen, A. Didemnin B induces apoptosis in proliferating but not resting peripheral blood mononuclear cells.Apoptosis7, 407–412 (2002).

     Article CAS PubMed  Google Scholar 

106. Bresters, D. et al.In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development.Leukemia17, 1338–1343 (2003).

     Article CAS PubMed  Google Scholar 

107. Gomez, S. G., Bueren, J. A., Faircloth, G. T., Jimeno, J. & Albella, B.In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.Exp. Hematol.31, 1104–1111 (2003).

     Article CAS PubMed  Google Scholar 

108. Taraboletti, G. et al. Antiangiogenic activity of aplidine, a new agent of marine origin.Br. J. Cancer90, 2418–2424 (2004).

     Article CAS PubMed PubMed Central  Google Scholar 

109. Perez, M., Sadqi, M., Munoz, V. & Avila, J. Inhibition by Aplidine of the aggregation of the prion peptide PrP 106–126 into β-sheet fibrils.Biochem. Biophys. Acta1639, 133–139 (2003).

     CAS PubMed  Google Scholar 

110. Talpir, R., Benayahu, Y., Kashman, Y., Pannell, L. & Schleyer, M. Hemiasterlin and geodiamolide TA: two new cytotoxic peptides from the marine spongeHemiasterella minor (Kirkpatrick).Tetrahedron Lett.35, 4453–4456 (1994).

     Article CAS  Google Scholar 

111. Coleman, J. E., de Silva, E. D., Kong, F., Andersen, R. J. & Allen, T. M. Cytotoxic peptides from the marine spongeCymbastela sp.Tetrahedron51, 10653–10662 (1995).

     Article CAS  Google Scholar 

112. Coleman, J. E., Patrick, B. O., Andersen, R. J. & Rettig, S. J. Hemiasterlin methyl ester.Acta Cryst. Sec. CC52, 1525–1527 (1996).

     Article CAS  Google Scholar 

113. Gamble, W. R. et al. Cytotoxic and tubulin-interactive hemiasterlins fromAuletta sp. andSiphonochalina spp. sponges.Bioorg. Med. Chem.7, 1611–1615 (1999).

     Article CAS PubMed  Google Scholar 

114. Anderson, H. J., Coleman, J. E., Andersen, R. J. & Roberge, M. Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation.Cancer Chemother. Pharmacol.39, 223–226 (1997).

     Article CAS PubMed  Google Scholar 

115. Bai, R., Durso, N. A., Sackett, D. L. & Hamel, E. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.Biochemistry38, 14302–14310 (1999).

     Article CAS PubMed  Google Scholar 

116. Nieman, J. A. et al. Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues.J. Nat. Prod.66, 183–199 (2003).

     Article CAS PubMed  Google Scholar 

117. Zask, A. et al. Synthesis and biological activity of analogues of the antimicrotubule agentN,β,β-trimethyl-L-phenylalanyl-N¹-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]-N¹,3-dimethyl-L-valinamide(HTI-286).J. Med. Chem.47, 4774–4786 (2004).

     Article CAS PubMed  Google Scholar 

118. Zask, A. et al. D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors.Bioorg. Med. Chem. Lett.14, 4353–4358 (2004).

     Article CAS PubMed  Google Scholar 

119. Yamashita, A. et al. Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment.Bioorg. Med. Chem. Lett.14, 5317–5322 (2004).

     Article CAS PubMed  Google Scholar 

120. Niu, C. et al. Tubulin inhibitors. Synthesis and biological activity of HTI-286 analogs with B-segment heterosubstituents.Bioorg. Med. Chem. Lett.14, 4329–4332 (2004).

     Article CAS PubMed  Google Scholar 

121. Lo, M. C. et al. Probing the interaction of HTI-286 with tubulin using a stilbene analogue.J. Am. Chem. Soc.126, 9898–9899 (2004).

     Article CAS PubMed  Google Scholar 

122. Krishnamurthy, G. et al. Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules.Biochemistry42, 13484–13495 (2003).

     Article CAS PubMed  Google Scholar 

123. Mitra, A. & Sept, D. Localization of the antimitotic peptide and depsipeptide binding site on β-tubulin.Biochemistry43, 13955–13962 (2004).

     Article CAS PubMed  Google Scholar 

124. Nunes, M. et al. Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label α-tubulin.Biochemistry44, 6844–6857 (2005).

     Article CAS PubMed  Google Scholar 

125. Poruchynsky, M. S. et al. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in α- or β-tubulin and increased microtubule stability.Biochemistry43, 13944–13954 (2004).

     Article CAS PubMed  Google Scholar 

126. Loganzo, F. et al. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in α-tubulin.Mol. CancerTher.3, 1319–1327 (2004).

     CAS  Google Scholar 

127. Loganzo, F. et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistancein vitro andin vivo.Cancer Res.63, 1838–1845 (2003).

     CAS PubMed  Google Scholar 

128. Ratain M. J. et al. Phase 1 and pharmacological study of HTI-286, a novel antimicrotubule agent: correlation of neutropenia with time above a threshold serum concentration.Proc. Am. Soc. Clin. Oncol.22, 516 (2003).

     Google Scholar 

129. Hadaschik, B. A. et al. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlinInt. J. Cancer:122, 2368–2376 (2008).

     Article CAS PubMed  Google Scholar 

130. Kalesse, M. The chemistry and biology of discodermolide.ChemBiochem1, 171–175 (2000).

     Article CAS PubMed  Google Scholar 

131. De Souza, M. V. (+)-discodermolide: a marine natural product against cancer.Scientific World Journal4, 415–436 (2004).

     Article PubMed PubMed Central CAS  Google Scholar 

132. Longley, R. E., Caddigan, D., Harmody, D., Gunasekera, M. & Gunasekera, S. P. Discodermolide — a new, marine-derived immunosuppressive compound. I.In vitro studies.Transplantation52, 650–656 (1991).

     Article CAS PubMed  Google Scholar 

133. Longley, R. E., Caddigan, D., Harmody, D., Gunasekera, M. & Gunasekera, S. P. Discodermolide — a new, marine-derived immunosuppressive compound. II.In vivo studies.Transplantation52, 656–661 (1991).

     Article CAS PubMed  Google Scholar 

134. Longley, R. E., Gunasekera, S. P., Faherty, D., McLane, J. & Dumont, F. Immunosuppression by discodermolide.Ann. NY Acad. Sci.696, 94–107 (1993).

     Article CAS PubMed  Google Scholar 

135. Gunasekera, S. P., Gunasekera, M., Longley, R. E. & Schulte, G. K. Discodermolide: a new bioactive polyhydroxylated lactone from the marine spongeDiscodermia dissoluta.J. Org. Chem.55, 4912–4915 (1990).

     Article CAS  Google Scholar 

136. Gunasekera, S. P., Gunasekera, M., Longley, R. E. & Schulte, G. K. Discodermolide: a new bioactive polyhydroxylated lactone from the marine spongeDiscodermia dissoluta [Erratum to document cited in CA113(9):75187b].J. Org. Chem.56, 1346 (1991).

     Article CAS  Google Scholar 

137. Nerenberg, J. B., Hung, D. T., Somers, P. K. & Schreiber, S. L. Total synthesis of the immunosuppressive agent (−)-discodermolide.J. Am. Chem. Soc.115, 12621–12622 (1993).

     Article CAS  Google Scholar 

138. Hung, D. T., Nerenberg, J. B. & Schreiber, S. L. Distinct binding and cellular properties of synthetic (+)- and (−)-discodermolides.Chem. Biol.1, 67–71 (1994).A good example of enantioselective bioactivity of natural and unnatural antipodes of marine-derived drugs.

     Article CAS PubMed  Google Scholar 

139. Harried, S. S., Lee, C. P., Yang, G., Lee, T. I. & Myles, D. C. Total synthesis of the potent microtubule-stabilizing agent (+)-discodermolide.J. Org. Chem.68, 6646–6660 (2003).

     Article CAS PubMed  Google Scholar 

140. Paterson, I. & Lyothier, I. Total synthesis of (+)-discodermolide: an improved endgame exploiting a Still-Gennari-type olefination with a C1-C8 β-ketophosphonate fragment.Org. Lett.6, 4933–4936 (2004).

     Article CAS PubMed  Google Scholar 

141. Paterson, I. et al. A second-generation total synthesis of (+)-discodermolide: the development of a practical route using solely substrate-based stereocontrol.J. Org. Chem.70, 150–160 (2005).

     Article CAS PubMed  Google Scholar 

142. Smith, A. B. 3rd, Kaufman, M. D., Beauchamp, T. J., LaMarche, M. J. & Arimoto, H. Gram-scale synthesis of (+)-discodermolide.Org. Lett.1, 1823–1826 (1999).

     Article CAS PubMed  Google Scholar 

143. Smith, A. B. 3rd et al. Evolution of a gram-scale synthesis of (+)-discodermolide.J. Am. Chem. Soc.122, 8654–8664 (2000).

     Article CAS  Google Scholar 

144. Smith, A. B. 3rd, Freeze, B. S., Brouard, I. & Hirose, T. A practical improvement, enhancing the large-scale synthesis of (+)-discodermolide: a third-generation approach.Org. Lett.5, 4405–4408 (2003).

     Article CAS PubMed  Google Scholar 

145. Mickel, S. J. et al. Large-scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 1: synthetic strategy and preparation of a common precursor.Org. Proc. Res. Dev.8, 92–100 (2004).

     Article CAS  Google Scholar 

146. Mickel, S. J. et al. Large-scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 2: synthesis of fragments C1–6 and C9–14Org. Proc. Res. Dev.8, 101–106 (2004).

     Article CAS  Google Scholar 

147. Mickel, S. J. et al. Large-scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 3: synthesis of fragment C15–21Org. Proc. Res. Dev.8, 107–112 (2004).References 145–147 describe the challenge for production, met by a tour de force multi-step, total synthesis, of a complex, rare marine-derived drug. The synthesis of 65 g of discodermolide shows what is possible when the target is highly desirable.

     Article CAS  Google Scholar 

148. Mickel, S. J. et al. Large-scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 4: preparation of fragment C7–24Org. Proc. Res. Dev.8, 113–121 (2004).

     Article CAS  Google Scholar 

149. Mickel, S. J. et al. Large-scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 5: linkage of fragments C1–6 and C7–24 and finale.Org. Proc. Res. Dev.8, 122–130 (2004).

     Article CAS  Google Scholar 

150. Hung, D. T., Chen, J. & Schreiber, S. L. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest.Chem. Biol.3, 287–293 (1996).

     Article CAS PubMed  Google Scholar 

151. ter Haar, E. et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol.Biochemistry35, 243–250 (1996).

     Article CAS PubMed  Google Scholar 

152. Kowalski, R. J. et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.Mol. Pharmacol.52, 613–622 (1997).

     Article CAS PubMed  Google Scholar 

153. Martello, L. A. et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines.Clin. Cancer Res.6, 1978–1987 (2000).

     CAS PubMed  Google Scholar 

154. Giannakakou, P. & Fojo, T. Discodermolide: just another microtubule-stabilizing agent? No! A lesson in synergy.Clin. Cancer Res.6, 1613–1615 (2000).

     CAS PubMed  Google Scholar 

155. Honore, S. et al. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells.Cancer Res.64, 4957–4964 (2004).

     Article CAS PubMed  Google Scholar 

156. Chen, J. G. & Horwitz, S. B. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.Cancer Res.62, 1935–1938 (2002).

     CAS PubMed  Google Scholar 

157. Broker, L. E. et al. Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells.Cancer Res.62, 4081–4088 (2002).

     CAS PubMed  Google Scholar 

158. Honore, S. et al. Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation.Mol. Cancer Ther.2, 1303–1311 (2003).

     CAS PubMed  Google Scholar 

159. Kar, S., Florence, G. J., Paterson, I. & Amos, L. A. Discodermolide interferes with the binding of tau protein to microtubules.FEBS Lett.539, 34–36 (2003).

     Article CAS PubMed  Google Scholar 

160. Escuin, D., Kline, E. R. & Giannakakou, P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1α accumulation and activity by disrupting microtubule function.Cancer Res.65, 9021–9028 (2005).

     Article CAS PubMed PubMed Central  Google Scholar 

161. Klein, L. E., Freeze, B. S., Smith, A. B. & Horwitz, S. B. The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence.Cell Cycle4, 501–507 (2005).

     Article CAS PubMed  Google Scholar 

162. Smith, A. B. 3rd et al. Discodermolide analogues as the chemical component of combination bacteriolytic therapy.Bioorg. Med. Chem. Lett.15, 3623–3626 (2005).

     Article CAS PubMed  Google Scholar 

163. Mita, A. et al. A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies.J. Clin. Oncol.22, 2025 (2004).

     Article  Google Scholar 

164. Schwartz, R. E. et al. Pharmaceuticals from cultured algae.J. Ind. Microbiol.5, 113–124 (1990).

     Article CAS  Google Scholar 

165. Trimurtulu, G. et al. Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green-algaNostoc sp strain Gsv-224.J. Am. Chem. Soc.116, 4729–4737 (1994).

     Article CAS  Google Scholar 

166. Kobayashi, M. et al. Arenastatin A, a potent cytotoxic depsipeptide from the Okinawan marine spongeDysidea arenaria.Tetrahedron Lett.35, 7969–7972 (1994).

     Article CAS  Google Scholar 

167. Barrow, R. A. et al. Total synthesis of cryptophycins — revision of the structures of cryptophycin-A and cryptophycin-C.J. Am. Chem. Soc.117, 2479–2490 (1995).

     Article CAS  Google Scholar 

168. Lu, K., Dempsey, J., Schultz, R. M., Shih, C. & Teicher, B. A. Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells.Cancer Chemother. Pharmacol.47, 170–178 (2001).

     Article CAS PubMed  Google Scholar 

169. Mooberry, S. L., Taoka, C. R. & Busquets, L. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.Cancer Lett.107, 53–57 (1996).

     Article CAS PubMed  Google Scholar 

170. Kerksiek, K., Mejillano, M. R., Schwartz, R. E., George, G. I. & Himes, R. H. Interaction of cryptophycin 1 with tubulin and microtubules.FEBS Lett.377, 59–61 (1995).

     Article CAS PubMed  Google Scholar 

171. Smith, C. D. & Zhang, X. Q. Mechanism of action of cryptophycin — interaction with the vinca alkaloid domain of tubulin.J. Biol. Chem.271, 6192–6198 (1996).

     Article CAS PubMed  Google Scholar 

172. Panda, D., Himes, R. H., Moore, R. E., Wilson, L. & Jordan, M. A. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.Biochemistry36, 12948–12953 (1997).

     Article CAS PubMed  Google Scholar 

173. Wagner, M. M. et al.In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines.Cancer Chemother. Pharmacol.43, 115–125 (1999).

     Article CAS PubMed  Google Scholar 

174. Sessa, C. et al. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.Eur. J. Cancer38, 2388–2396 (2002).

     Article CAS PubMed  Google Scholar 

175. Stevenson, J. P. et al. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.Clin. Cancer Res.8, 2524–2529 (2002).

     CAS PubMed  Google Scholar 

176. Edelman, M. J. et al. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.Lung Cancer39, 197–199 (2003).

     Article PubMed  Google Scholar 

177. Liang, J. et al. Cryptophycins-309, 249 and other cryptophycin analogs: Preclinical efficacy studies with mouse and human tumors.Investig. New Drugs23, 213–224 (2005).

     Article CAS  Google Scholar 

178. Pettit, G. R. The dolastatins.Fortschr. Chem. Org. Naturst.70, 1–79 (1997).

     CAS PubMed  Google Scholar 

179. Pettit, G. R. et al. The isolation and structure of a remarkable marine animal antineoplastic constituent — Dolastatin 10.J. Am. Chem. Soc.109, 6883–6885 (1987).

     Article CAS  Google Scholar 

180. Pettit, G. R. Progress in the discovery of biosynthetic anticancer drugs.J. Nat. Prod.59, 812–821 (1996).

     Article CAS PubMed  Google Scholar 

181. Pettit, G. R. et al. The absolute-configuration and synthesis of natural (−)-Dolastatin-10.J. Am. Chem. Soc.111, 5463–5465 (1989).

     Article CAS  Google Scholar 

182. Bai, R., Pettit, G. R. & Hamel, E. Dolastatin-10, a powerful cytostatic peptide derived from a marine animal — inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.Biochem. Pharmacol.39, 1941–1949 (1990).

     Article CAS PubMed  Google Scholar 

183. Bai, R., Pettit, G. R. & Hamel, E. Binding of dolastatin-10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.J. Biol. Chem.265, 17141–17149 (1990).

     Article CAS PubMed  Google Scholar 

184. Bai, R., Friedman, S. J., Pettit, G. R. & Hamel, E. Dolastatin-15, a potent antimitotic depsipeptide derived fromDolabella auricularia: interaction with tubulin and effects on cellular microtubules.Biochem. Pharmacol.43, 2637–2645 (1992).

     Article CAS PubMed  Google Scholar 

185. Verdier-Pinard, P., Kepler, J. A., Pettit, G. R. & Hamel, E. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.Mol. Pharmacol.57, 180–187 (2000).

     Article CAS PubMed  Google Scholar 

186. Pitot, H. C. et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.Clin. Cancer Res.5, 525–531 (1999).

     CAS PubMed  Google Scholar 

187. Madden, T. et al. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.Clin. Cancer Res.6, 1293–1301 (2000).

     CAS PubMed  Google Scholar 

188. Vaishampayan, U. et al. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.Clin. Cancer Res.6, 4205–4208 (2000).

     CAS PubMed  Google Scholar 

189. Krug, L. M. et al. Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.Ann. Oncol.11, 227–228 (2000).

     Article CAS PubMed  Google Scholar 

190. Margolin, K. et al. Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium.Invest. New Drugs19, 335–340 (2001).

     Article CAS PubMed  Google Scholar 

191. Saad, E. D. et al. Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.Am. J. Clin. Oncol.25, 451–453 (2002).

     Article PubMed  Google Scholar 

192. von Mehren, M. et al. Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas.Sarcoma8, 107–111 (2004).

     Article CAS PubMed PubMed Central  Google Scholar 

193. Perez, E. A. et al. Phase II trial of dolastatin-10 in patients with advanced breast cancer.Invest. New Drugs23, 257–261 (2005).

     Article CAS PubMed  Google Scholar 

194. Kindler, H. L. et al. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.Invest. New Drugs23, 489–493 (2005).

     Article CAS PubMed  Google Scholar 

195. Newman, D. J. & Cragg, G. M. Marine natural products and related compounds in clinical and advanced preclinical trials.J. Nat. Prod.67, 1216–1238 (2004).

     Article CAS PubMed  Google Scholar 

196. Kobayashi, M. et al. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.Jpn. J.Cancer Res.88, 316–327 (1997).

     CAS  Google Scholar 

197. Schoffski, P. et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.Ann. Oncol.15, 671–679 (2004).

     Google Scholar 

198. de Jonge, M. J. et al. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.Clin. Cancer Res.11, 3806–3813 (2005).

     Article CAS PubMed  Google Scholar 

199. Hashiguchi, N. et al. TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply.Anticancer Res.24, 2201–2208 (2004).

     CAS PubMed  Google Scholar 

200. Natsume, T. et al. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.Jpn. J. Cancer Res.91, 737–747 (2000).

     Article CAS PubMed PubMed Central  Google Scholar 

201. Hirata, Y. & Uemura, D., Halichondrins — antitumor polyether macrolides from a marine sponge.Pure App. Chem.58, 701–710 (1986).

     Article CAS  Google Scholar 

202. Uemura, D. et al. Norhalichondrin A: an antitumor polyether macrolide from a marine sponge.J. Am. Chem. Soc.107, 4796–4798 (1985).

     Article CAS  Google Scholar 

203. Pettit, G. R. et al. Isolation and structure of halistatin 1 from the eastern Indian Ocean marine spongePhakellia carteri.J. Org. Chem.58, 2538–2543 (1993).

     Article CAS  Google Scholar 

204. Pettit, G. R. et al. Antineoplastic agents. 219. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine spongeAxinella sp.J. Med. Chem.34, 3339–3340 (1991).

     Article CAS PubMed  Google Scholar 

205. Bai, R. L. et al. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.J. Biol. Chem.,266, 15882–15889 (1991).

     Article CAS PubMed  Google Scholar 

206. Dabydeen, D. A. et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.Mol. Pharmacol.70, 1866–1875 (2006).

     Article CAS PubMed  Google Scholar 

207. Aicher, T. D et al. Total synthesis of halichondrin B and norhalichondrin B.J. Am. Chem. Soc.114, 3162–3164 (1992).

     Article CAS  Google Scholar 

208. Hart, J. B., Lill, R. E., Hickford, S. J. H., Blunt, J. W. & Munro, M. H. G. inDrugs from the Sea (ed. Fusetani, N.) 134–153 (Karger, Basel, 2000).

     Book  Google Scholar 

209. Gravalos, D. G., Lake, R., Blunt, J. W., Munro, M. H. G. & Litaudon, M. S. P. Halichondrins: cytotoxic polyether macrolides. EP0572109 (B1) (1993).

210. Munro, M. H. G. et al. The discovery and development of marine compounds with pharmaceutical potential.J. Biotechnol.70, 15–25 (1999).

     Article CAS PubMed  Google Scholar 

211. Stamos, D. P., Sean, S. C. & Kishi, Y. New synthetic route to the C14-C38 segment of halichondrins.J. Org. Chem.62, 7552–7553 (1997).

     Article CAS  Google Scholar 

212. Wang, Y., Habgood, G. J., Christ, W. J., Kishi, Y., Littlefield, B. A. & Yu, M. J. Structure–activity relationships of halichondrin B analogues: modifications at C30-C38.Bioorg. Med. Chem. Lett.,10, 1029–1032 (2000).

     Article CAS PubMed  Google Scholar 

213. Littlefield, B. A. et al. Macrocyclic analogs and methods of their use and preparation. WO9965894 (A1) (1999).

214. Yu, M. J., Kishi, Y. & Littlefield, B. A. inAnticancer Agents from Natural Products (eds Cragg, G. M., Kingston, D. G. I. & Newman, D. J.) 241–265 (Taylor and Francis, Boca Raton, 2005).

     Google Scholar 

215. Towle, M. J. et al.In vitro andin vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B.Cancer Res.61, 1013–1021 (2001).

     CAS PubMed  Google Scholar 

216. Forero, J. B. et al. E7389, a novel anti-tubulin, in patients with refractory breast cancer.J. Clin. Oncol.24 (Suppl. 18), 653 (2006).

     Article  Google Scholar 

217. Blum, J. L. et al. Phase II study of eribulin mesylate (E7389) halichondrin B analog in patients with refractory breast cancer.J. Clin. Oncol.25 (Suppl. 18), 1034 (2007).

     Article  Google Scholar 

218. Spira, A. I., et al. Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC).J. Clin. Oncol.25 (Suppl. 18), 7546 (2007).

     Article  Google Scholar 

219. PR Newswire. Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients With Advanced Breast Cancer.PR Newswire web site [online], <http://www.prnewswire.co.uk/cgi/news/release?id=227511> (2008).

220. Hamann, M. T. & Scheuer, P. J. Kahalalide F: a bioactive depsipeptide from the Sacoglossan molluskElysia rufescens and the green algaBryopsis sp.J. Am. Chem. Soc.115, 5825–5826 (1993).

     Article CAS  Google Scholar 

221. Goetz, G., Yoshida, W. Y. & Scheuer, P. J. The absolute stereochemistry of kahalalide F.Tetrahedron55, 7739–7746 (1999).

     Article CAS  Google Scholar 

222. Hamann, M. T., Otto, C. S., Scheuer, P. J. & Dunbar, D. C. Kahalalides: bioactive peptide from a marine molluskElysia rufescens and its algal dietBryopsis sp.J. Org. Chem.61, 6594–6600 (1996).

     Article CAS PubMed  Google Scholar 

223. Minami, Y. et al. Structure of cypemycin, a new peptide antibiotic.Tetrahedron Lett.35, 8001–8004 (1994).

     Article  Google Scholar 

224. Neuhof, T. et al. Hassallidin A, a glycosylated lipopeptide with antifungal activity from the cyanobacteriumHassallia sp.J. Nat. Prod.68, 695–700 (2005).

     Article CAS PubMed  Google Scholar 

225. Becerro, M. A., Goetz, G., Paul, V. J. & Scheuer, P. J. Chemical defenses of the sacoglossan molluskElysia rufescens and its host algaBryopsis sp.J. Chem. Ecol.27, 2287–2299 (2001).

     Article CAS PubMed  Google Scholar 

226. Lopez-Macia, A., Jimenez, J. C., Royo, M., Giraet, E. & Albericio, F. Synthesis and structure determination of kahalalide F.J. Am. Chem. Soc.123, 11398–11401 (2001).

     Article CAS PubMed  Google Scholar 

227. Bonnard, I., Manzanares, I. & Rinehart, K. L. Stereochemistry of kahalalide F.J. Nat. Prod.66, 1466–1470 (2003).

     Article CAS PubMed  Google Scholar 

228. Garcia-Rocha, M., Bonay, P. & Avila, J. The antitumoral compound Kahalalide F acts on cell lysosomes.Cancer Lett.99, 43–50 (1996).

     Article CAS PubMed  Google Scholar 

229. Suarez, Y. et al. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells.Mol. Cancer Ther.2, 863–872 (2003).

     CAS PubMed  Google Scholar 

230. Janmaat, M. L., Rodriguez, J. A., Jimeno, J., Kruyt, F. A. E. & Giaccone, G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling.Mol. Pharmacol.68, 502–510 (2005).

     Article CAS PubMed  Google Scholar 

231. Sewell, J. M. et al. The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines.Eur. J. Cancer41, 1637–1644 (2005).

     Article CAS PubMed  Google Scholar 

232. Sparidans, R. W. et al. Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.Anticancer Drugs12, 575–582 (2001).

     Article CAS PubMed  Google Scholar 

233. Brown, A. P., Morrissey, R. L., Faircloth, G. T. & Levine, B. S. Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat.Cancer Chemother. Pharmacol.50, 333–340 (2002).

     Article CAS PubMed  Google Scholar 

234. Rademaker-Lakhai, J. M. et al. Phase I clinical and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer.Clin.Cancer Res.11, 1854–1862 (2005).

     CAS  Google Scholar 

235. Ciruelos, C. et al. A phase I clinical and pharmacokinetic (PK) study with Kahalalide F (KF) in patients (pts) with advanced solid tumors (AST) with a continuous weekly (W) 1-hour iv infusion schedule.Eur. J. Cancer38 (Suppl.), S33 (2002).

     Google Scholar 

236. Pettit, G. R. et al. Isolation and structure of bryostatin-1.J. Am. Chem. Soc.104, 6846–6848 (1982).

     Article CAS  Google Scholar 

237. Schaufelberger, D. E. et al. The large-scale isolation of bryostatin-1 fromBugula neritina following current good manufacturing practices.J. Nat. Prod.54, 1265–1270 (1991).

     Article CAS PubMed  Google Scholar 

238. Rouhi, M. A. Supply issues complicate trek of chemicals from sea to market.Chem. Eng. News73, 42–44 (1995).

     Article  Google Scholar 

239. Evans, D. A. et al. Total synthesis of bryostatin 2.J. Am. Chem. Soc.121, 7540–7552 (1999).

     Article CAS  Google Scholar 

240. Ohmori, K. et al. Total synthesis of bryostatin 3.Angew. Chem. Int. Ed. Engl.39, 2290–2294 (2000).

     Article CAS PubMed  Google Scholar 

241. Ohmori, K. Evolution of synthetic strategies for highly functionalized natural products: a successful route to bryostatin 3.Bull. Chem. Soc. Jap.77, 875–885 (2004).

     Article CAS  Google Scholar 

242. Kageyama, M. et al. Synthesis of bryostatin-7.J. Am. Chem. Soc.112, 7407–7408 (1990).

     Article CAS  Google Scholar 

243. Blanchette, M. A. et al. Synthesis of bryostatins.1. construction of the C(1)-C(16) fragment.J. Org. Chem.54, 2817–2825 (1989).

     Article CAS  Google Scholar 

244. Voight, E. A., Seradi, H., Roethle, P. A. & Burke, S. D. Synthesis of the bryostatin 1 northern hemisphere (C1-C16) via desymmetrization by ketalization/ring-closing metathesis.Org. Lett.6, 4045–4048 (2004).

     Article CAS PubMed  Google Scholar 

245. DeBrabander, J. & Vandewalle, M. Towards the asymmetric synthesis of bryostatin 1.Pure Appl. Chem.68, 715–718 (1996).

     Article CAS  Google Scholar 

246. Isakov, N., Galron, D., Mustelin, T., Pettit, G. R. & Altman, A. Inhibition of phorbol ester-induced T-cell proliferation by bryostatin is associated with rapid degradation of protein-kinase-C.J. Immunol.150, 1195–1204 (1993).

     CAS PubMed  Google Scholar 

247. Wender, P. A. et al. Synthesis of the first members of a new class of biologically active bryostatin analogues.J. Am. Chem. Soc.120, 4534–4535 (1998).

     Article CAS  Google Scholar 

248. Wender, P. A. et al. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C.Proc. Natl Acad. Sci. USA85, 7197–7201 (1988).

     Article CAS PubMed PubMed Central  Google Scholar 

249. Hennings, H. et al. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin.Carcinogenesis8, 1343–1346 (1987).

     Article CAS PubMed  Google Scholar 

250. Berkow, R. L. et al.In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.Cancer Res.53, 2810–2815 (1993).

     CAS PubMed  Google Scholar 

251. Hu, Z. B., Ma, W. L., Uphoff, C. C., Lanotte, M. & Drexler, H. G. Modulation of gene-expression in the acute promyelocytic leukemia-cell line Nb4.Leukemia7, 1817–1823 (1993).

     CAS PubMed  Google Scholar 

252. Grant, S., Pettit, G. R. & McCrady, C. Effect of bryostatin-1 on thein vitro radioprotective capacity of recombinant granulocyte macrophage colony-stimulating factor (Rgm-Csf) toward committed human myeloid progenitor cells (Cfu-Gm).Exp. Hematol.20, 34–42 (1992).

     CAS PubMed  Google Scholar 

253. Mutter, R. & Wills, M. Chemistry and clinical biology of the bryostatins.Bioorg. Med. Chem.8, 1841–1860 (2000).

     Article CAS PubMed  Google Scholar 

254. Propper, D. J. et al. A phase II study of bryostatin 1 in metastatic malignant melanoma.Br. J. Cancer78, 1337–1341 (1998).

     Article CAS PubMed PubMed Central  Google Scholar 

255. Varterasian, M. et al. Phase I trial of bryostatin 1 in relapsed lymphoma and CLL.Blood88, 2269 (1996).

     Google Scholar 

256. Varterasian, M. L. et al. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.Invest. New Drugs19, 245–247 (2001).

     Article CAS PubMed  Google Scholar 

257. Varterasian, M. L. et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemiaClin. Cancer Res.6, 825–828 (2000).

     CAS PubMed  Google Scholar 

258. Grant, S. et al. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.Clin. Cancer Res.4, 611–618 (1998).

     CAS PubMed  Google Scholar 

259. Clamp, A. & Jayson, G. C. The clinical development of the bryostatins.Anticancer Drugs13, 673–683 (2002).

     Article CAS PubMed  Google Scholar 

260. Hickman, P. F. et al. Bryostatin 1, a novel antineoplastic agent and protein-kinase-C activator, induces human myalgia and muscle metabolic defects — a P-31 magnetic-resonance spectroscopic study.Br. J. Cancer72, 998–1003 (1995).

     Article CAS PubMed PubMed Central  Google Scholar 

261. Pfister, D. G. et al. A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.Invest. New Drugs20, 123–127 (2002).

     Article CAS PubMed  Google Scholar 

262. Zonder, J. A. et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.Clin. Cancer Res.7, 38–42 (2001).

     CAS PubMed  Google Scholar 

263. Bedikian, A. Y. et al. Phase II evaluation of bryostatin-1 in metastatic melanoma.Melanoma Res.11, 183–188 (2001).

     Article CAS PubMed  Google Scholar 

264. Pagliaro, L. et al. A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma.Cancer89, 615–618 (2000).

     Article CAS PubMed  Google Scholar 

265. Clamp, A. R. et al. A phase II trial of bryostatin-I administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma.Br. J. Cancer89, 1152–1154 (2003).

     Article CAS PubMed PubMed Central  Google Scholar 

266. Cragg, L. H. et al. Phase I trial and correlative laboratory studies of bryostatin I (NSC 339555) and high-dose 1-β-D-arabinofuranosylcytosine in patients with refractory acute leukemia.Clin. Cancer Res.8, 2123–2133 (2002).

     CAS PubMed  Google Scholar 

267. Dowlati, A. et al. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.Clin. Cancer Res.9, 5929–5935 (2003).

     CAS PubMed  Google Scholar 

268. Ajani, J. A. Multi-center Phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma.Invest. New Drugs24, 353–357 (2006).

     Article CAS PubMed  Google Scholar 

269. Schwartz, G. K. & Shah, M. A. Targeting the cell cycle: a new approach to cancer therapy.J. Clin. Oncol.23, 9408–9421 (2005).

     Article CAS PubMed  Google Scholar 

270. Feher, M. & Schmidt, J. M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry.J. Chem. Inf. Comput. Sci.43, 218–227 (2003).

     Article CAS PubMed  Google Scholar 

271. Udwary, D. W. et al. Genome sequencing reveals complex secondary metabolome in the marine actinomyceteSalinispora tropica.Proc. Natl Acad. Sci. USA104, 10376–10381 (2007).

     Article CAS PubMed PubMed Central  Google Scholar 

272. Newman, D. J. & Hill, R. T. New drugs from marine microbes: the tide is turning.J. Ind. Microbiol. Biotechnol.33, 539–544 (2006).

     Article CAS PubMed  Google Scholar 

273. Piel, J. Bacterial symbionts: prospects for the sustainable production of invertebrate-derived pharmaceuticals.Curr. Med. Chem.13, 39–50 (2006).

     Article CAS PubMed  Google Scholar 

274. Hildebrand, M. et al.bryA: An unusual modular polyketide synthase gene from the uncultivated bacterial symbiont of the marine bryozoanBugula neritina.Chem. Biol.11, 1543–1552 (2004).

     Article CAS PubMed  Google Scholar 

275. Sudek, S. et al. Identification of the putative bryostatin polyketide synthase gene cluster from “Candidatus Endobugula sertula”, the uncultivated microbial symbiont from the marine bryozoanBugula neritina. J. Nat. Prod.70, 67–74 (2007).

     Article CAS PubMed  Google Scholar 

276. Homer,The Iliad, (∼7^th century, B.C). Fagles, R. (translation). Penguin Books (1990).

     Google Scholar 

277. Homer,The Odyssey (∼7^th century B. C.). Fagles, R. (translation). Penguin Books (2006).

     Google Scholar 

278. Feling, R. H. et al. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genusSalinospora.Angew. Chem. Intl. Ed.42, 355–357 (2003).

     Article CAS  Google Scholar 

279. Maldonado, L., Fenical, W., Goodfellow, M., Jensen, P. R. & Ward, A. C.Salinispora gen nov., sp. nov.,Salinispora arenicola sp. nov., andS. tropica sp. nov., obligate marine actinomycetes belonging to the familyMicromonosporaceae.Internat. J. System. Appl. Microbiol.55, 1759–1766 (2005).

     Google Scholar 

280. Chauhan, D. et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.Cancer Cell8, 407–419 (2005).

     Article CAS PubMed  Google Scholar 

281. Chauhan, D. et al. Combination of proteasome inhibitors bortezomib and NPI-0052 triggerin vivo synergistic cytotoxicity in multiple myeloma.Blood111, 1654–1664 (2008).

     Article CAS PubMed PubMed Central  Google Scholar 

282. Fenicala, W. et al. Discovery and development of the anticancer agent salinosporamide A (NPI-0052).Bioorg. Med. Chem. 5 Nov 2008 (doi:10.1016/j.bmc.2008.10.075).This article, and several within the same issue of the journal, chronicle the discovery of key marine antitumour drugs by the original investigators and illustrates issues of procurement, scale-up, production and clinical investigations.

     Google Scholar 

283. Searle, P. A. & Molinski, T. F. Phorboxazoles A and B — potent cytostatic macrolides from marine spongePhorbas sp.J. Am. Chem. Soc.117, 8126–8131 (1995).

     Article CAS  Google Scholar 

284. Searle, P. A., Molinski, T. F., Brzezinski, L. J. & Leahy, J. W. Absolute configuration of phorboxazoles A and B from the marine spongePhorbas sp.1. macrolide and hemiketal rings.J. Am. Chem. Soc.118, 9422–9423 (1996).

     Article CAS  Google Scholar 

285. Molinski T. F. Absolute configuration of phorboxazoles A and B from the marine sponge,Phorbas sp.2. C43 and complete stereochemistry.Tetrahedron Lett.37, 7879–7880 (1996).

     Article CAS  Google Scholar 

286. Skepper, C. K., MacMillan, J. B., Zhou, G.-X., Masuno, M. N. & Molinski, T. F. Chlorocyclopropane macrolides from the marine spongePhorbas sp. Assignment of the absolute configurations of phorbasides A and B by quantitative CD.J. Am. Chem. Soc.129, 4150–4151 (2007).

     Article CAS PubMed  Google Scholar 

287. MacMillan, J. B., Xiong-Zhou, G., Skepper, C. K. & Molinski, T. F. Phorbasides A-E, cytotoxic chlorocyclopropane macrolide glycosides from the marine sponge Phorbas sp. CD determination of C-methyl sugar configurations.J. Org. Chem.73, 3699–3706 (2008).

     Article CAS PubMed  Google Scholar 

Download references